Long-term follow-up reveals survival outcomes in adolescents and young adults with acute lymphoblastic leukemia, suggesting the importance of minimal residual disease.
Key Points
The estimated 10-year overall survival for adolescents and young adults with acute lymphoblastic leukemia was 64%.
Achieving minimal residual disease negativity significantly improved long-term survival outcomes, with 10-year OS for MRD negative patients at 68.9%.
Observational analysis from the RJ-ALL 2014 protocol demonstrated promising results for newly diagnosed BCR::ABL1-negative acute lymphoblastic leukemia patients.
The findings underscore the significance of minimal residual disease status when predicting prognosis in acute lymphoblastic leukemia.